Dechert Advises Royalty Pharma on Its Acquisition of Massachusetts General Hospital Royalty Interest in Entyvio
March 10, 2020
March 10, 2020
PHILADELPHIA, Pennsylvania, March 10 -- Dechert, a law firm, issued the following news:
Dechert advised Royalty Pharma on IP-related matters in its acquisition of Massachusetts General Hospital's royalty interest in Entyvio (vedolizumab), a monoclonal antibody that is used in the treatment of ulcerative colitis and Crohn's disease, two of the most common forms of inflammatory bowel disease.
Entyvio was approved by the U.S. Food & Drug Administration in 2014 and is a . . .
Dechert advised Royalty Pharma on IP-related matters in its acquisition of Massachusetts General Hospital's royalty interest in Entyvio (vedolizumab), a monoclonal antibody that is used in the treatment of ulcerative colitis and Crohn's disease, two of the most common forms of inflammatory bowel disease.
Entyvio was approved by the U.S. Food & Drug Administration in 2014 and is a . . .